OmniTAC: Effectome-wide platform for next-generation bifunctional molecules discovery
OmniTAC is an innovative discovery engine that identifies bifunctional molecules (BFMs) by scanning over 50 effector protein classes, enabling rapid identification of protein-protein interactions for enhanced therapeutic potential. Ideal for pharmaceutical development.
Overview
OmniTAC is a pioneering effectome-wide discovery platform designed to revolutionize the identification of next-generation bifunctional molecules (BFMs). Unlike traditional methods restricted to specific effector protein classes like E3 ligases, OmniTAC surveys a comprehensive range of over 50 effector protein classes. This breadth allows OmniTAC to identify optimal protein-protein interactions (PPIs) for intracellular therapeutic targets, enhancing the potential to discover BFMs with superior therapeutic benefits and broader applicability.
Technical specifications
- Effectome-wide scanning: Utilizes a wide spectrum of effector protein classes for PPI discovery.
- Library creation: Develops BFM libraries based on specific targets using proprietary EP ligand library.
- Cell assays and optimization: Establishes target-specific cell lines and assays to validate PPIs, followed by computational optimization for lead compound characteristics.
- In vitro testing: Synthesizes and tests BFMs to confirm activity.
Technology readiness level
OmniTAC is currently at Technology Readiness Level 3, indicating it has been validated through active research and development. Future plans include expanding its validation through comprehensive cell assays and computational optimization to enhance its applicability and success rate in therapeutic discovery.
About General Proximity
General Proximity is a biotechnology company that has developed OmniTAC, a proprietary, mechanism-agnostic discovery engine designed to identify effector proteins capable of modulating disease-driving, previously undruggable targets. The platform functions by identifying and facilitating specific proximity events between target and effector proteins, allowing for precise control of biological processes such as activation, refolding, or degradation. By leveraging this generalized approach, the company moves beyond traditional small-molecule limitations to discover therapeutic candidates for a broad range of biological pathways that were previously beyond the reach of medicine.
This technology is central to the company’s efforts to develop next-generation therapeutics for high-impact areas, including oncology, cardiometabolic disease, neurodegeneration, and longevity. The company’s innovative approach has garnered significant industry recognition and support, including non-dilutive grants from ARPA-H and the NIH’s National Cancer Institute, multiple pharmaceutical Golden Ticket awards, and a strategic multi-target collaboration with Daiichi Sankyo. By focusing on the effector-driven regulation of biology, General Proximity aims to address critical unmet medical needs and pioneer a new paradigm in induced-proximity drug discovery.
delivered to your inbox.